

1 **Title:** Differentiating the Effect of Medication and Illness on Brain Volume Reductions in
2 First-Episode Psychosis: A Longitudinal, Randomized, Triple-blind, Placebo-controlled MRI
3 Study.

4
5 **Authors:** Sidhant Chopra*, Alex Fornito*, Shona M. Francey PhD, Brian O'Donoghue,
6 Vanessa Croyley, Barnaby Nelson, Jessica Graham, Lara Baldwin, Steven Tahtalian, Hok
7 Pan Yuen, Kelly Allott, Mario Alvarez-Jimenez, Susy Harrigan, Kristina Sabaroedin,
8 Christos Pantelis, Stephen J Wood, Patrick McGorry

9
10 ***Authors contributed equally**

11
12 **Corresponding Author:** Alex Fornito (alex.fornito@monash.edu)
13 Turner Institute of Brain and Mental Health
14 770 Blackburn Road, Clayton, Victoria
15 Australia

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Abstract**

36

37 Changes in brain volume are a common finding in Magnetic Resonance Imaging (MRI)
38 studies of people with psychosis and numerous longitudinal studies suggest that volume
39 deficits progress with illness duration. However, a major unresolved question concerns
40 whether these changes are driven by the underlying illness or represent iatrogenic effects of
41 antipsychotic medication. Here, we report MRI findings from a triple-blind randomised
42 placebo-controlled study where 62 antipsychotic-naïve patients with first episode psychosis
43 (FEP) received either an atypical antipsychotic or a placebo pill over a treatment period of 6
44 months. Both FEP groups received intensive psychosocial therapy. A healthy control group
45 (n=27) was also recruited. Structural MRI scans were obtained at baseline, 3-months and 12-
46 months. Our primary aim was to differentiate illness-related brain volume changes from
47 medication-related changes within the first 3 months of treatment. We secondarily
48 investigated long-term effects at the 12-month timepoint. From baseline to 3 months, we
49 observed a significant group x time interaction in the pallidum ($p < 0.05$ FWE-corrected),
50 such that patients receiving antipsychotic medication showed increased volume, patients on
51 placebo showed decreased volume, and healthy controls showed no change. In patients, a
52 greater increase in pallidal grey matter volume over 3 months was associated with a greater
53 reduction in symptom severity. We additionally found preliminary evidence for illness-
54 related volume reductions in prefrontal cortices at 12 months and medication-related volume
55 reductions in cerebellum at both 3-months and 12-months. Our findings indicate that
56 psychotic illness and antipsychotic exposure exert distinct and spatially distributed effects on
57 brain volume. Our results align with prior work in suggesting that the therapeutic efficacy of
58 antipsychotic medications may be primarily mediated through their effects on the basal
59 ganglia.

60

61

62 Introduction

63

64 Magnetic Resonance Imaging (MRI) has been used extensively to document brain changes in
65 psychotic disorders. Grey matter volume (GMV) reductions relative to healthy controls are
66 particularly robust, and evident across all illness stages^{1 2 3} and in multiple brain regions^{4 5 2}.
67 Some of these changes appear to worsen with transition to psychosis and ongoing illness⁶,
68 which has been taken as evidence of a progressive process associated with illness onset⁷,
69 although some have opposed this view^{8,9}.

70

71 Numerous mechanisms have been proposed to explain longitudinal brain changes in
72 schizophrenia, including aberrant neurodevelopment¹⁰, neuroinflammation¹¹, network-based
73 pathological spread¹², and the iatrogenic effects of antipsychotic treatment^{4,13}. In particular,
74 widespread and early treatment of patients with antipsychotics has made it notoriously
75 difficult to disentangle the effects of medication and pathophysiology on brain volume.
76 Although studies of antipsychotic-naïve patients clearly show brain GMV reductions in the
77 absence of medication², several lines of evidence suggest that antipsychotic medication
78 influences GMV¹⁴. For example, longitudinal studies suggest that cumulative exposure to
79 antipsychotic medication is associated with reduced total cerebral¹³ and prefrontal GMV⁴,
80 and studies in macaques have shown that chronic exposure to typical and atypical
81 antipsychotics reduces total GMV¹⁵ and glial cell number¹⁶. One recent placebo-controlled
82 trial in mostly remitted patients with psychotic depression showed that, compared to patients
83 on placebo, those given olanzapine had decreased cortical thickness within both
84 hemispheres¹⁷.

85

86 Other work suggests that antipsychotic medication, particularly atypicals, may exert a
87 neuroprotective effect¹⁸. Studies in rodents have supported a neuroprotective effect of
88 atypicals¹⁹, which may arise through several candidate mechanisms, including neurogenesis¹⁹
89 and protection against oxidative stress²¹. This work parallels naturalistic²² and experimental¹⁸
90 longitudinal MRI studies in human patients suggesting that atypical antipsychotics may be
91 associated with less GMV loss when compared to typical antipsychotics.

92

93 One limitation affecting all existing longitudinal studies conducted thus far is that they have
94 only examined patients who are receiving antipsychotic medication. This approach is
95 problematic because previous exposure to medication may result in brain changes that could


96 mask or be mistaken for illness-related processes. The only way to unambiguously
97 distinguish illness-related from medication-related brain changes is through a randomized
98 placebo-controlled study of antipsychotic naïve first-onset patients, in which one patient
99 group is exposed to antipsychotic medication and the other receives a placebo. This design is
100 able to test several distinct hypotheses about the differential contributions of illness and
101 antipsychotics to brain changes in the earliest illness stages (Figure 1). However, such
102 experiments are difficult to conduct due to the practical difficulties and ethical concerns
103 associated with withholding antipsychotic treatment.

104

105 We recently overcame these challenges to conduct, to our knowledge, the first randomized,
106 triple-blind, placebo-controlled trial of antipsychotic medication in first-episode psychosis
107 (FEP), in which antipsychotic-naïve patients were randomized to receive psychosocial
108 therapy with or without antipsychotic medication over the first six months of treatment
109 engagement²³. We found, using a non-inferiority design²³, that the placebo group showed
110 comparable clinical and functional outcomes to the medicated group at the end of the
111 treatment study²⁴. Here, we report an analysis of GMV in this cohort, where MRI was
112 acquired before treatment (baseline), at three months, and then at a 12-month follow-up. Our
113 primary aim was to distinguish volumetric changes attributable to illness from those
114 attributable to antipsychotic medication within the initial 3-month period (Figure 1). Our
115 secondary aim was to investigate longer-term changes at the 12-month follow-up, after a
116 period of time in which both groups had been exposed to antipsychotics. We also examined
117 whether any observed volumetric changes were associated with symptomatic and functional
118 changes.

119

120



121

122 Figure 1. *Disentangling illness-related and antipsychotic medication-induced brain changes in early psychosis*

123 *using a randomized placebo-controlled design. Each panel presents a schematic of expected results under*

124 different hypotheses. (A) A medication-related decline due to antipsychotics is indicated if medicated patients
125 show accelerated GMV loss compared to patients in the placebo group and healthy controls. (B) An illness
126 effect that is not modified by treatment is indicated if both treatment groups show accelerated GMV loss relative
127 to controls. (C) An illness-related change that is rescued by antipsychotics is indicated if GMV loss is observed
128 in the placebo group but not medicated patients. (D) Antipsychotic-related hypertrophy, where GMV is
129 increased in the medicated group compared to the healthy controls and/or placebo group, could be consistent
130 with either a possible medication-related rescue or the initial stages of a volume-loss process (e.g., an oedemic
131 reaction). These possibilities could be disentangled by examining correlations with symptomatic or functional
132 measures; e.g., an association between the volumetric increase and improved outcome would be consistent with
133 possible rescue. For simplicity, controls are depicted as showing no change over time, but they may also show
134 longitudinal increases or decreases. The key factor is whether the rate of change is greater in patients compared
135 to controls. Solid lines represent group means and shaded areas represent some estimate of the error around the
136 mean.

137

138

139 **Method**

140

141 Study Design

142

143 Patients were randomized to one of two groups: one given antipsychotic medication plus
144 intensive psychosocial therapy (MIPT) and the other given a placebo plus intensive
145 psychosocial therapy (PIPT) ([Figure 2](#)). A third healthy control group who received no
146 intervention was also recruited. For both patient groups, the treatment period spanned six
147 months. MRI and clinical assessments were conducted at baseline, three months, and a final
148 follow-up at 12 months. The randomization phase of the study terminated at 6 months, so
149 patients in either the MIPT or PIPT group could have received antipsychotic medication and
150 ongoing psychosocial interventions in between the 6 and 12 months into the study. Further
151 research and safety protocols can be found in the Supplement and elsewhere²³.

152

153 Participants

154

155 Patients were aged 15-25 yrs and were experiencing a first episode of psychosis, defined as
156 fulfilling Structured Clinical Interview for DSM-5 (SCID) criteria for a psychotic disorder,
157 including schizophrenia, schizophreniform disorder, delusional disorder, brief psychotic
158 disorder, major depressive disorder with psychotic symptoms, substance-induced psychotic
159 disorder or psychosis not otherwise specified. Additional inclusion criteria to minimise risk


160 were: ability to provide informed consent; comprehension of English language; no
 161 contraindication to MRI scanning; duration of untreated psychosis (DUP) of less than 6
 162 months; living in stable accommodation; low risk to self or others; minimal previous
 163 exposure to antipsychotic medication (< 7 days of use or lifetime 1750mg chlorpromazine
 164 equivalent exposure; further details provided in [Supplementary Table 1](#)).

165

166 Healthy control participants were aged between 18 and 25, could provide written informed
 167 consent, and were psychiatrically, neurologically and medically healthy. A stratified
 168 randomisation design, with Gender and DUP as factors, was used to allocate patients to either
 169 MIPT or PIPT treatment groups. DUP was included as a three-level factor (0-30 days, 31-90
 170 days, and >90 days). Clinicians, patients, study assessors and researchers conducting MRI
 171 pre-processing remained blinded to treatment allocation throughout the trial. Further details
 172 on inclusion criteria, safety measures, and discontinuation criteria can be found elsewhere²³.
 173 A recruitment flow diagram and final group numbers at each time point are presented in
 174 [Figure 2](#) and demographic are presented in [Table 1](#).

175

176



177

178 Figure 2 – Recruitment flow diagram for the patient group.

179

180

181 Symptomatic and functional measures

182

183 The preregistered primary and secondary trial outcome measures were the total Social and
184 Occupational Functioning Assessment Scale (SOFAS) and the BPRS-4 scores respectively²³.
185 Additional measures can be found in Supplementary materials.

186

187 Antipsychotic Medication

188

189 Patients randomised to the MIPT group received either 1mg risperidone (n=25) or 3mg
190 paliperidone (n=5). To reflect real-world clinical treatment, this starting dose was then
191 increased according to clinical response by the blinded treating clinician. The same procedure
192 was followed for participants in the PIPT group, who received a placebo pill that was
193 identical in taste, appearance, and packaging to the active medication. Additional details can
194 be found in [Supplementary materials](#).

195

196 MRI acquisition and pre-processing

197

198 A 3-T Siemens Trio Tim scanner located at the Royal Children's Hospital in Melbourne,
199 Australia, was used to acquire a high resolution structural T1-weighted scan for each
200 participant. Pre-processing of scan was done using the Computational Anatomy Toolbox and
201 Diffeomorphic Anatomical Registration Exponentiated Lie algebra algorithm (DARTEL)²⁵.
202 Additional details can be found in [Supplementary materials](#).

203

204 Statistical analyses

205

206 Mixed effects marginal models were used to analyse regional GMV across the three groups
207 (MIPT, PIPT and Healthy control) and three-time points (baseline, three-months and 12-
208 months follow-up). The models were implemented at voxel-level in the Sandwich Estimator
209 Toolbox²⁶ (version 2.1.0). All other statistical analyses were conducted in R-studio (version
210 1.1.423).

211

212 Our primary analyses sought to disentangle the effects of medication and illness (e.g., [Figure](#)
213 [1](#)) on total GMV and to map localised changes using VBM. This analysis focused on the

214 baseline and 3-month timepoints, as they fell within the treatment period. For both total and
 215 regional GMV, we first tested for baseline differences between groups using an analysis of
 216 covariance (ANCOVA), controlling for age at baseline, sex, handedness and total intracranial
 217 volume. We then examined longitudinal changes using a marginal model. The voxel-level
 218 analysis was implemented in the Sandwich Estimator Toolbox²⁶ (version 2.1.0), which uses
 219 ordinary least squares estimators of group-level regression parameters and a modified
 220 sandwich estimator for standard errors²⁷. This method allows for robust and accurate
 221 estimation of random effects while mitigating problems posed by mis-specification of
 222 covariance structure when using traditional mixed-effects models²⁶. The contrast of interest
 223 was a group (MIPT, PIPT, Control) by time (baseline, 3-month) interaction. We performed
 224 inference using non-parametric bootstrapping (10,000 bootstraps), with statistical
 225 significance for total volume assessed at $p < 0.05$, and a $p < 0.05$, family-wise error (FWE)-
 226 corrected threshold for voxel-level analyses, as implemented in the Sandwich Estimator
 227 Toolbox²⁶. To provide a more complete picture, we also report results surviving a less
 228 stringent threshold of $p < 0.001$, uncorrected, with an extent threshold of 10 voxels, but
 229 caution that these findings require replication. Our secondary analysis included the 12-month
 230 timepoint and was designed to examine the long-term effects of early withholding of
 231 antipsychotic medication. Similar procedures were used as in the primary analysis. Details of
 232 the 12-month analysis and of analyses addressing symptom correlates and confounding
 233 variables, are in the Supplement.

234

235 **Results**

236

237 *Demographics and clinical characteristics*

238

239 There were no significant differences between the patient and control samples in sex or
 240 handedness, but the patients were, on average, 1.9 years younger and had 2 years less
 241 education ([Table 1](#)). At baseline, the two patient groups (PIPT and MIPT) did not
 242 significantly differ in age, education, sex, handedness, BPRS or SOFAS score.

243

	First episode psychosis		Healthy control (N=27)	T / χ^2 (p) †
	PIPT (N =30)	MIPT (N=29)		
Baseline age, years (SD)	18.8 (2.72)	19.5 (2.94)	21.9 (1.93)	-4.49 (<0.001)

Females, N (%)	14 (46.6%)	13 (44.8%)	17 (62.9%)	2.19 (0.139)
Handedness, Left , N (%)	2 (6.7%)	2 (6.9%)	3 (11.1%)	0.465 (0.495)
Education, years (SD)	11.8 (1.86)	12.7 (2.30)	15.2 (1.90)	-6.21 (0.001)
Diagnosis, N				
Major depression with psychosis	7	5	-	
Schizophreniform disorder	5	5	-	
Psychotic disorder NOS	8	7	-	
Substance-induced psychotic disorder	4	2	-	
Delusional disorder	1	4	-	
Schizophrenia	5	5	-	
Missing diagnosis	0	1	-	
Baseline BPRS Total, mean (SD)	59.4 (9.64)	55.8 (10.10)	-	1.40 (0.166)
Baseline SOFAS, mean (SD)	52.9 (14.0)	51.7 (10.6)	-	0.384 (0.703)
Baseline SANS, mean (SD)	37.3 (17.2)	32.9 (18.1)	-	0.961 (0.346)
Baseline HAM-D, mean (SD)	19.5 (6.75)	18.2 (6.57)	-	0.745 (0.459)
Baseline HAM-A, mean (SD)	22.2 (6.42)	20.2 (7.25)	-	1.118 (0.268)
Baseline QLS, mean (SD)	68.5 (24)	70.6 (20.8)	-	-0.368 (0.714)

244

245 Table 1 – Sample characteristics and group differences at baseline. Abbreviations: PIPT = placebo plus
246 intensive psychosocial therapy, MIPT = antipsychotic medication plus intensive psychosocial therapy; NOS =
247 not otherwise specified; BPRS = Brief Psychiatric Rating Scale version 4; SOFAS = Social and Occupational
248 Functioning Assessment Scale. SANS = Scale for the Assessment of Negative Symptoms; HAM-D = Hamilton
249 Depression Rating Scale; HAM-A = Hamilton Anxiety Rating SCALE; QLS = Quality of Life Scale. † This
250 column provides the T or χ^2 values comparing the healthy control and patients (collapsed across two treatment
251 conditions) at baseline.

252

253

254

255 *Baseline differences in total and regional grey matter volume*

256

257 No significant baseline difference in total GMV was detected between patients (collapsed
258 across treatment groups) and healthy control participants ($F = 0.297$; $p = 0.588$), nor were any

259 voxel-level regional differences detected following whole-brain FWE-correction. Results at
260 an uncorrected threshold can be found in Supplementary Table 3.

261

262

263 *Disentangling medication-related and illness-related brain changes in the first three months*
264 *of treatment*

265

266 No significant group by time interaction in total GMV was detected between the three groups
267 ($F = 0.387$, $p = 0.689$). Using VBM to map regional changes, a significant group by time
268 interaction was identified within the right pallidum ($p < 0.05$, FWE-corrected; [Figure 3a](#)).

269 From baseline to 3 months, GMV in this region remained stable in controls, decreased in the
270 PIPT group, and increased in the MIPT group ([Figure 3b](#)). The primary post-hoc contrasts
271 revealed that, compared to baseline, pallidal GMV significantly decreased in PIPT patients (t
272 $= 2.34$, $p = 0.021$), increased in MIPT patients ($t = -2.20$, $p = 0.029$), and did not change in
273 controls ($t = -0.142$, $p = 0.888$). Secondary post-hoc contrasts conducted at the 3-month
274 timepoint showed that the PIPT had significantly less pallidal GMV than the MIPT ($t = -2.26$,
275 $p = 0.012$), with neither group differing from controls.

276


277 Greater increase in pallidal GMV over 3 months was associated with a greater reduction in
278 symptom severity, as indexed by the BPRS Total score ($\rho = -0.418$; $p = 0.017$; [Figure 3c](#)).

279 There was no significant association with SOFAS total score ($\rho = -0.002$; $p = 0.998$), and
280 none of the exploratory correlations with ancillary measures survived correction for multiple
281 comparisons. At an uncorrected threshold, we found a negative correlation between right
282 pallidal volume and BRPS positive symptom change scores that was comparable in
283 magnitude to the association with BPRS total ($\rho = -0.431$; $p = 0.012$), suggesting that the
284 relationship between pallidal volume and symptom change may be specifically related to
285 positive symptoms.

286

287

288



289

290 Figure 3 – (A): Red = Location of the cluster within the right pallidum where significant group x time
 291 interaction ($p < 0.05$, FWE-corrected) was detected. (B): The principal pallidal GMV eigenvariate for each
 292 group at baseline and 3-month follow-up, adjusted for model covariates. Error bars show 95% confidence
 293 intervals. (C): The association between percentage change (% Δ) in total Brief Psychiatric Rating Scale score
 294 (BPRS; y-axis) and percentage change in pallidal GMV volume within the two treatment groups.

295

296

297 At an uncorrected threshold ($k > 10$, $p < 0.001$), we identified interactions between group and
 298 time that were consistent with a unmodified illness-related effect within lateral occipital
 299 cortex (Supplementary [Figure 2a](#), [Figure 1b](#)); a medication-related decline within cerebellum
 300 ([Supplementary Figure 2b](#), [Figure 1a](#)); and medication-related hypertrophy within the inferior
 301 temporal cortex, precuneus, and orbitofrontal cortex ([Supplementary Figure 2c-e](#), [Figure 1d](#)).

302

303

304

305 *Potential confounds*

306

307 No statistically significant associations between percentage change in pallidal volume
 308 between baseline and 3 months and DUP, concomitant medication use, or substance use were
 309 detected. Details are in the [Supplementary materials](#).

310

311 *Disentangling medication-related and illness-related brain changes in the first 12 months of* 312 *treatment*

313

314 We next considered MRI measures at the 12-month follow-up to differentiate the long-term
 315 effects of medication and illness. Patients retained at the 12-month follow up did not
 316 significantly differ in baseline age ($t = 1.7858$, $p = 0.08$), sex ($\chi^2 = 0.087$, $p = 0.767$),

317 education ($t = 0.652$, $p = 0.518$), BPRS ($t = -0.076$, $p = 0.940$) or SOFAS ($t = 0.780$, $p =$
318 0.439) from those who did not complete the 12-month follow up scan.

319

320 No statistically significant differences in linear trend for total GMV over the 12-month
321 follow-up period were detected ($F = 1.60$, $p = 0.192$). At the voxel-level, no statistically
322 significant regional differences were identified at the FWE-corrected threshold. At $p < 0.001$
323 ($k=10$) uncorrected, there were differences in linear trend consistent with unmodified illness-
324 related changes ([Figure 1b](#)) within the bilateral dorsolateral superior frontal gyrus (
325 [Supplementary Figure 3a-b](#)), right superior orbito-frontal gyrus ([Supplementary Figure 3c](#)),
326 middle orbito-frontal gyrus ([Supplementary Figure 3d](#)), and left superior medial frontal gyrus
327 ([Supplementary Figure 3e](#)); a medication-related decline ([Figure 1a](#)) within the right
328 cerebellar crus I ([Supplementary Figure 3f](#)); and medication-related hypertrophy ([Figure 1d](#))
329 within the right middle temporal gyrus ([Supplementary Figure 3g](#)), temporal pole
330 ([Supplementary Figure 3h](#)) and cerebellar VIII ([Supplementary Figure 3i](#)). The results were
331 largely consistent when eight individuals within the PIPT group who were exposed to
332 antipsychotic medication between the 3- and 12-month scans were removed from the analysis
333 ([Supplementary Figure 1](#)).

334

335 Additionally, we assessed whether the changes seen within pallidal cluster detected in the
336 primary analysis persisted at 12-month follow-up. The differences between the three groups
337 were not statistically significant ([Supplementary Figure 4](#)).

338

339 *Assessing the specificity of findings to grey matter*

340

341 To assess the specificity of our findings to grey matter, we repeated the above primary and
342 secondary analyses in white matter. For the primary analysis, we found a significant group by
343 time interaction within a small area of the left cerebellar lobule IX white matter ($k = 9$, $p <$
344 0.05 , FWE-corrected; [Supplementary Figure 5a](#)). From baseline to 3 months, white matter
345 volume in this region increased in the controls ($t = -2.34$, $p = 0.021$), remained stable in the
346 PIPT group ($t = 0.216$, $p = 0.830$), and decreased in the MIPT group ($t = 2.239$, $p = 0.027$).
347 This pattern of results is consistent with medication-related volume loss (e.g., [Figure 1a](#)). The
348 change in volume within this cluster was not correlated with change in BPRS-4 or SOFAS.
349 Results at an uncorrected threshold can be found in [Supplementary Materials](#).

350

351

352 **Discussion**

353

354 We used a triple-blind, placebo-controlled randomized trial to disentangle the effects of
355 medication and illness on GMV change within early stages of first episode psychosis. We
356 found evidence of regionally heterogeneous effects associated with both illness and
357 medication, with the most robust effect being an illness-related decline of pallidal GMV in
358 the placebo group coupled with an antipsychotic-related increase in the medicated group.
359 Consistent with a therapeutic benefit of the antipsychotic-induced increase in pallidal GMV,
360 a greater volumetric change in this area was associated with a greater reduction in
361 symptomology within the first three months of illness. Preliminary evidence ($k=10$, $p <$
362 0.001 , uncorrected) for unmodified illness-related changes and medication-related decline
363 were identified in visual cortex and cerebellum, respectively.

364

365 Our secondary analysis of long-term changes assessed at 12-month follow-up revealed
366 preliminary evidence of an unmodified illness-related GMV reduction in prefrontal cortex,
367 medication-related decline in cerebellum, and medication-related hypertrophy in temporal
368 areas. Together, these results suggest that both psychotic illness and medication exposure
369 exert distinct and spatially distributed effects on GMV, and converge with prior work in
370 suggesting that the therapeutic efficacy of antipsychotic medications is primarily mediated
371 through their effects on the basal ganglia²⁸.

372

373 *Illness-related volumetric reductions in FEP*

374

375 Pallidal volume in the PIPT group declined over the first three months of illness. This decline
376 was not associated with substance use or concomitant medication, which would be consistent
377 with an illness-related effect. In contrast, MIPT patients showed an increase in pallidal
378 volume over time. Thus, antipsychotic medication appears to prevent or perhaps even reverse
379 illness-related volume loss in this part of the brain.

380

381 Using less stringent criteria for significance, we found evidence for illness-related GMV
382 reductions in visual cortex within the first three months of illness, and further reductions in
383 prefrontal cortex by the 12-month time point. Frontal white matter reductions were also

384 identified at the 12-month time point. These changes were observed in both the PIPT and
385 MIPT groups, suggesting that they are unmodified effects of illness.

386

387 The pallidum is the primary output structure of the striatum, and disturbances of fronto-
388 striato-thalamic circuits have long been implicated in the pathogenesis of psychosis²⁹. The
389 function of these circuits is heavily modulated by dopamine, and their disruption is apparent
390 in diagnosed patients³⁰, patients' unaffected first-degree relatives³⁰ and individuals
391 experiencing an at-risk mental state for psychosis³¹. Functional connectivity within this
392 circuit also correlates with the severity of psychotic-like experiences in non-clinical
393 samples³². Thus, one hypothesis that may explain our findings is that altered signalling from
394 the striatum triggers early volumetric loss in the pallidum^{29,33}, which subsequently spreads to
395 affect functionally-related prefrontal areas^{34,35}. This interpretation aligns with evidence that
396 smaller pallidal volume in anti-psychotic naïve patients is associated with more severe
397 psychiatric symptomology³⁶, and our own finding that increased pallidal volume over the first
398 three months correlates with improved symptom outcome. Moreover, our finding of possible
399 long-term reductions in prefrontal cortex grey and white matter may explain why prefrontal
400 dysfunction is so commonly reported in patients with established illness. However, we
401 caution that the precise mechanisms underlying volumetric changes in psychosis remain a
402 topic of debate^{8,9}. Here, we show that some of these changes cannot be attributed to
403 medication and other confounding factors, but more subtle influences such as differences in
404 hydration, physical and mental activity, and stress levels cannot be ruled out. Targeted
405 mechanistic studies are required before we can draw strong inferences about
406 pathophysiological mechanisms.

407

408 *Are antipsychotics neuroprotective?*

409

410 The increase of pallidal volume seen in MIPT patients, together with the correlation between
411 increased pallidal GMV and symptom improvement between baseline and three months, are
412 consistent with a putative neuroprotective effect of atypical antipsychotic medication (Figure
413 1d). Larger pallidal volumes have been widely reported in medicated³⁷ but not antipsychotic
414 naïve³⁸ patients. Human studies have also shown reduced volume loss in patients taking
415 atypical compared to patients receiving typical antipsychotic medication¹⁸, and work in
416 animals indicates that atypicals can exert several neuroprotective effects¹⁹, including
417 induction of neurogenesis²⁰, and protection against oxidative stress²¹, as well as positive

418 effects on cognition³⁹. Our results are in line with this work and suggest that atypicals prevent
419 illness-related volume loss occurring early in the illness. However, we caution that MRI is
420 unable to identify a specific cellular mechanism that would support a neuroprotection
421 hypothesis, and the molecular mechanisms by which atypical medications might protect grey
422 matter structures in humans are poorly understood. Atypicals are characterized by relatively
423 high affinities for both serotonin and dopamine receptors⁴⁰. Patients in our study received
424 risperidone or its molecularly similar active metabolite paliperidone. Both medications are
425 antagonists for 5HT₂ receptors in addition to showing high affinity for D₂ receptors⁴¹. Rodent
426 studies using risperidone have demonstrated cell proliferation⁴², increased levels of brain-
427 derived neurotrophic factor⁴³, and the promotion of antioxidant defence⁴⁴. Thus, while our
428 data suggest that antipsychotics may rescue or perhaps reverse illness-related decline of
429 pallidal volume within the first three months of illness, and that this apparent preservation of
430 volume is associated with improved symptom outcomes, further studies are required to
431 elucidate underlying cellular and molecular mechanisms.

432

433 Notably, pallidal volume had normalized in both MIPT and PIPT patients by 12 months
434 (Supplementary Figure 4). While it is possible that this normalisation reflects differences in
435 illness characteristics between patients who did and did not complete the 12 months follow-
436 up, we found no significant difference in baseline demographic and clinical characteristics
437 between these two groups. Nonetheless, it is possible that patients completing the 12-month
438 assessment followed distinct illness trajectories after enrolment into the study. An alternative
439 explanation is that early pallidal changes reflect an acute illness effect with subsequent
440 normalisation reflecting a compensatory process. It is also possible that intensive
441 psychosocial therapy and engagement with clinical services was sufficient to normalize
442 volumes⁴⁵.

443

444 *Evidence of medication-related decline in grey matter volume*

445

446 We found no evidence for antipsychotic-related decline in GMV at whole-brain-corrected
447 thresholds. At the less stringent, uncorrected threshold, we observed consistent medication-
448 related GMV reductions in the cerebellum at 3 months and at 12 months (Figure 1a). Similar
449 results surviving whole-brain correction were observed in cerebellar white matter. While
450 previous naturalistic⁴ and experimental¹⁷ studies have demonstrated an association between
451 antipsychotic medication and loss of both total and hemispheric volume, our study is distinct

452 in several important ways. First, our study included a placebo control and healthy control,
453 allowing us to experimentally isolate the effect of atypical antipsychotic medication. Second,
454 we examined patients during a relatively short time span of one year, while other studies have
455 examined longer periods⁴. Third, the mean cumulative dosage of antipsychotic medication in
456 our study, while still an effective dose⁴⁶, is considered low. Fourth, all participants in our
457 study were scanned with the same scanner, mitigating the potentially confounding effects of
458 scanner differences. Finally, all patients within our study received an evidence-based
459 psychosocial intervention which may have associated neuroprotective effects⁴⁵. In light of
460 these differences, our results could be interpreted as preliminary evidence of potential
461 neurotoxicity in early illness stages that is predominantly expressed in the cerebellum.
462 However, we note that there was no association between volume change within the
463 cerebellum and change in functional or symptom outcome scores, in either grey or white
464 matter. Longer-term follow-up would be required to determine the extent to which further
465 volume-loss emerges with additional antipsychotic exposure.

466

467 *Strengths and limitations*

468 The strengths of this study include a prospective randomised control trial design,
469 antipsychotic naïve patients, triple blinding to treatment, and the inclusion of a healthy
470 control group as a reference for characterizing normative change over time. We also used
471 robust non-parametric inference to model longitudinal changes in GMV²⁶. In order for this
472 study to satisfy ethical concerns, our inclusion criteria meant that patients who entered the
473 study posed low risk of harm to self or others, lived in stable accommodation, and had a short
474 DUP. Additionally, patients who did not improve in clinical symptomology or functioning
475 were removed from the trial, which contributed to attrition. It is therefore possible that our
476 final patient cohort represents a sub-sample of individuals with a lower severity of illness,
477 and that the changes we report here are a conservative estimate of those that would be
478 observed in a more heterogeneous sample. However, we note that the mean baseline SOFAS
479 scores of our patients were comparable to epidemiologically representative cohorts of FEP
480 patients⁴⁷ and that the mean baseline BPRS score of patients within our study (57.6) would
481 classify them as ‘markedly ill’⁴⁸. Additionally, there were no differences in baseline clinical
482 or demographic characteristics between patients who did and did not complete the study.
483 Thus, prima facie, there are few obvious differences between our cohort and many FEP
484 samples reported in the literature, beyond the strict safety requirements of our study.
485 Nonetheless, we cannot rule out the possibility that patients who remained in the study have a

486 form of psychotic illness that is perhaps less severe and/or progressive than those who did not
487 complete. A final limitation is that we only examined risperidone and paliperidone. It remains
488 to be seen whether our results generalize to other antipsychotic medications.

489

490 Conclusion

491 Taken together, our results demonstrate that psychotic illness and antipsychotic exposure
492 exert distinct and spatially distributed effects on brain volume, with the most robust effect
493 being consistent with an antipsychotic-related rescue of pallidal volume changes in the early
494 stages of treatment.

495

496

497

498

499

500

501

502

503

504

505

506

507

508

References

509

- 510 1. Jung, W. H. *et al.* Cortical Thickness Reduction in Individuals at Ultra-High-Risk for
511 Psychosis. *Schizophr. Bull.* **37**, 839–849 (2011).
- 512 2. Fusar-Poli, P., Radua, J., McGuire, P. & Borgwardt, S. Neuroanatomical Maps of
513 Psychosis Onset: Voxel-wise Meta-Analysis of Antipsychotic-Naive VBM Studies.
514 *Schizophr. Bull.* **38**, 1297–1307 (2012).

- 515 3. Fornito, A., Yücel, M., Patti, J., Wood, S. J. & Pantelis, C. Mapping grey matter
516 reductions in schizophrenia: An anatomical likelihood estimation analysis of voxel-based
517 morphometry studies. *Schizophr. Res.* **108**, 104–113 (2009).
- 518 4. Ho, B.-C., Andreasen, N. C., Ziebell, S., Pierson, R. & Magnotta, V. Long-term
519 Antipsychotic Treatment and Brain Volumes. *Arch. Gen. Psychiatry* **68**, 128–137 (2011).
- 520 5. van Erp, T. G. M. *et al.* Cortical Brain Abnormalities in 4474 Individuals With
521 Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics
522 Through Meta Analysis (ENIGMA) Consortium. *Biol. Psychiatry* **84**, 644–654 (2018).
- 523 6. Pantelis, C. *et al.* Neuroanatomical abnormalities before and after onset of psychosis: a
524 cross-sectional and longitudinal MRI comparison. *The Lancet* **361**, 281–288 (2003).
- 525 7. van Haren, N. E. M., Cahn, W., Hulshoff Pol, H. E. & Kahn, R. S. Schizophrenia as a
526 progressive brain disease. *Eur. Psychiatry* **23**, 245–254 (2008).
- 527 8. Zipursky, R. B., Reilly, T. J. & Murray, R. M. The Myth of Schizophrenia as a
528 Progressive Brain Disease. *Schizophr. Bull.* **39**, 1363–1372 (2013).
- 529 9. Weinberger, D. R. & Radulescu, E. Finding the Elusive Psychiatric “Lesion” With 21st-
530 Century Neuroanatomy: A Note of Caution. *Am. J. Psychiatry* **173**, 27–33 (2016).
- 531 10. Weinberger, D. R. Implications of Normal Brain Development for the Pathogenesis of
532 Schizophrenia. *Arch. Gen. Psychiatry* **44**, 660–669 (1987).
- 533 11. Miller, B. J. & Goldsmith, D. R. Towards an Immunophenotype of Schizophrenia:
534 Progress, Potential Mechanisms, and Future Directions. *Neuropsychopharmacology* **42**,
535 299–317 (2017).
- 536 12. Wannan, C. M. J. *et al.* Evidence for Network-Based Cortical Thickness Reductions in
537 Schizophrenia. *Am. J. Psychiatry* [appi.ajp.2019.18040380](https://doi.org/10.1176/appi.ajp.2019.18040380) (2019)
538 [doi:10.1176/appi.ajp.2019.18040380](https://doi.org/10.1176/appi.ajp.2019.18040380).

- 539 13. Veijola, J. *et al.* Longitudinal Changes in Total Brain Volume in Schizophrenia: Relation
540 to Symptom Severity, Cognition and Antipsychotic Medication. *PLOS ONE* **9**, e101689
541 (2014).
- 542 14. Fusar-Poli, P. *et al.* Progressive brain changes in schizophrenia related to antipsychotic
543 treatment? A meta-analysis of longitudinal MRI studies. *Neurosci. Biobehav. Rev.* **37**,
544 1680–1691 (2013).
- 545 15. Dorph-Petersen, K.-A. *et al.* The Influence of Chronic Exposure to Antipsychotic
546 Medications on Brain Size before and after Tissue Fixation: A Comparison of
547 Haloperidol and Olanzapine in Macaque Monkeys. *Neuropsychopharmacology* **30**,
548 1649–1661 (2005).
- 549 16. Konopaske, G. T. *et al.* Effect of chronic antipsychotic exposure on astrocyte and
550 oligodendrocyte numbers in macaque monkeys. *Biol. Psychiatry* **63**, 759–765 (2008).
- 551 17. Voineskos, A. N. *et al.* Effects of Antipsychotic Medication on Brain Structure in
552 Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging
553 Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. *JAMA*
554 *Psychiatry* (2020) doi:10.1001/jamapsychiatry.2020.0036.
- 555 18. Lieberman, J. A. *et al.* Antipsychotic Drug Effects on Brain Morphology in First-Episode
556 Psychosis. *Arch. Gen. Psychiatry* **62**, 361–370 (2005).
- 557 19. Chen, A. T. & Nasrallah, H. A. Neuroprotective effects of the second generation
558 antipsychotics. *Schizophr. Res.* (2019) doi:10.1016/j.schres.2019.04.009.
- 559 20. Nasrallah, H. A., Hopkins, T. & Pixley, S. K. Differential effects of antipsychotic and
560 antidepressant drugs on neurogenic regions in rats. *Brain Res.* **1354**, 23–29 (2010).
- 561 21. Shao, Y., Peng, H., Huang, Q., Kong, J. & Xu, H. Quetiapine mitigates the
562 neuroinflammation and oligodendrocyte loss in the brain of C57BL/6 mouse following
563 cuprizone exposure for one week. *Eur. J. Pharmacol.* **765**, 249–257 (2015).

- 564 22. van Haren, N. E. M. Changes in Cortical Thickness During the Course of Illness in
565 Schizophrenia. *Arch. Gen. Psychiatry* **68**, 871 (2011).
- 566 23. O'Donoghue, B. *et al.* Staged treatment and acceptability guidelines in early psychosis
567 study (STAGES): A randomized placebo controlled trial of intensive psychosocial
568 treatment plus or minus antipsychotic medication for first-episode psychosis with low-
569 risk of self-harm or aggression. Study protocol and baseline characteristics of
570 participants. *Early Interv. Psychiatry* **0**,.
- 571 24. Francey, S. *et al.* Psychosocial Intervention with or without Antipsychotic Medication for
572 First Episode Psychosis: A Randomized Noninferiority Clinical Trial. *Schizophr. Bull.*
573 *Open* (In press).
- 574 25. Gaser, C. & Dahnke, R. CAT - A Computational Anatomy Toolbox for the Analysis of
575 Structural MRI Data. *HBM* 336–348 (2016).
- 576 26. Guillaume, B., Hua, X., Thompson, P. M., Waldorp, L. & Nichols, T. E. Fast and
577 accurate modelling of longitudinal and repeated measures neuroimaging data.
578 *NeuroImage* **94**, 287–302 (2014).
- 579 27. Eicker. Asymptotic normality and consistency of the least squares estimators for families
580 of linear regressions. *Ann Math Stat* **34**, 447–456 (1963).
- 581 28. Howes, O. D. & Kapur, S. The dopamine hypothesis of schizophrenia: version III--the
582 final common pathway. *Schizophr. Bull.* **35**, 549–562 (2009).
- 583 29. Dandash, O., Pantelis, C. & Fornito, A. Dopamine, fronto-striato-thalamic circuits and
584 risk for psychosis. *Schizophr. Res.* **180**, 48–57 (2017).
- 585 30. Fornito, A. *et al.* Functional Dysconnectivity of Corticostriatal Circuitry as a Risk
586 Phenotype for Psychosis. *JAMA Psychiatry* **70**, 1143–1151 (2013).
- 587 31. Dandash, O. *et al.* Altered Striatal Functional Connectivity in Subjects With an At-Risk
588 Mental State for Psychosis. *Schizophr. Bull.* **40**, 904–913 (2014).

- 589 32. Sabaroedin, K. *et al.* Functional Connectivity of Corticostriatal Circuitry and Psychosis-
590 like Experiences in the General Community. *Biol. Psychiatry* **86**, 16–24 (2019).
- 591 33. Carlsson, A., Waters, N. & Carlsson, M. L. Neurotransmitter interactions in
592 schizophrenia--therapeutic implications. *Biol. Psychiatry* **46**, 1388–1395 (1999).
- 593 34. Fusar-Poli, P. *et al.* Abnormal frontostriatal interactions in people with prodromal signs
594 of psychosis: a multimodal imaging study. *Arch. Gen. Psychiatry* **67**, 683–691 (2010).
- 595 35. McCutcheon, R. A., Abi-Dargham, A. & Howes, O. D. Schizophrenia, Dopamine and the
596 Striatum: From Biology to Symptoms. *Trends Neurosci.* **42**, 205–220 (2019).
- 597 36. Spinks, R. *et al.* Globus pallidus volume is related to symptom severity in neuroleptic
598 naive patients with schizophrenia. *Schizophr. Res.* **73**, 229–233 (2005).
- 599 37. Hashimoto, N. *et al.* The effect of duration of illness and antipsychotics on subcortical
600 volumes in schizophrenia: Analysis of 778 subjects. *NeuroImage Clin.* **17**, 563–569
601 (2018).
- 602 38. Lang, D. J. *et al.* An MRI Study of Basal Ganglia Volumes in First-Episode
603 Schizophrenia Patients Treated With Risperidone. *Am. J. Psychiatry* **158**, 625–631
604 (2001).
- 605 39. Choy, K. H. C. *et al.* Positive Allosteric Modulation of the Muscarinic M1 Receptor
606 Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of
607 Behavior. *J. Pharmacol. Exp. Ther.* **359**, 354–365 (2016).
- 608 40. Meltzer, H. Y., Matsubara, S. & Lee, J. C. The ratios of serotonin₂ and dopamine₂
609 affinities differentiate atypical and typical antipsychotic drugs. *Psychopharmacol. Bull.*
610 **25**, 390–392 (1989).
- 611 41. Kapur, S., Zipursky, R. B. & Remington, G. Clinical and theoretical implications of 5-
612 HT₂ and D₂ receptor occupancy of clozapine, risperidone, and olanzapine in
613 schizophrenia. *Am. J. Psychiatry* **156**, 286–293 (1999).

- 614 42. Wakade, C. G., Mahadik, S. P., Waller, J. L. & Chiu, F.-C. Atypical neuroleptics
615 stimulate neurogenesis in adult rat brain. *J. Neurosci. Res.* **69**, 72–79 (2002).
- 616 43. Pillai, A., Terry, A. V. & Mahadik, S. P. Differential effects of long-term treatment with
617 typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and
618 hippocampus. *Schizophr. Res.* **82**, 95–106 (2006).
- 619 44. Stojković, T. *et al.* Risperidone reverses phencyclidine induced decrease in glutathione
620 levels and alterations of antioxidant defense in rat brain. *Prog. Neuropsychopharmacol.*
621 *Biol. Psychiatry* **39**, 192–199 (2012).
- 622 45. Eack, S. M. *et al.* Neuroprotective Effects of Cognitive Enhancement Therapy Against
623 Gray Matter Loss in Early Schizophrenia: Results From a 2-Year Randomized Controlled
624 Trial. *Arch. Gen. Psychiatry* **67**, 674–682 (2010).
- 625 46. McGorry, P. D. *et al.* Very Low-Dose Risperidone in First-Episode Psychosis: A Safe
626 and Effective Way to Initiate Treatment. *Schizophrenia Research and Treatment*
627 <https://www.hindawi.com/journals/schizort/2011/631690/> (2011)
628 doi:10.1155/2011/631690.
- 629 47. Henry, L. P. *et al.* The EPPIC Follow-Up Study of First-Episode Psychosis: Longer-Term
630 Clinical and Functional Outcome 7 Years After Index Admission. *J. Clin. Psychiatry* **71**,
631 716–728 (2010).
- 632 48. Leucht, S. *et al.* Clinical implications of Brief Psychiatric Rating Scale scores. *Br. J.*
633 *Psychiatry* **187**, 366–371 (2005).
- 634 49. Esteban, O. *et al.* MRIQC: Advancing the automatic prediction of image quality in MRI
635 from unseen sites. *PLOS ONE* **12**, e0184661 (2017).
- 636 50. Ashburner, J. A fast diffeomorphic image registration algorithm. *NeuroImage* **38**, 95–113
637 (2007).

638 51. ANZCTR - Registration.

639 [https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&isReview=tru](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82439&isReview=true)

640 e.

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667 Supplementary Materials

668

669 **Study Design and Funding – Additional Details**

670

671 The trial took place at the Early Psychosis Prevention and Intervention Centre, which is part
672 of Orygen Youth Health, Melbourne, Australia. The trial was registered with the Australian
673 New Zealand Clinical Trials Registry in November 2007 (ACTRN12607000608460) and
674 received ethics approval from the Melbourne Health Human Research and Ethics committee.
675

676 Role of Funding Sources: Janssen-Cilag partially supported the early years of this study with
677 an unrestricted investigator-initiated grant and provided risperidone, paliperidone and
678 matched placebo for the first 30 participants. The study was then funded by an Australian
679 National Health and Medical Research Project grant # 95757. The funders had no role in
680 study design, data collection, data analysis, data interpretation, or writing of this report. The
681 corresponding author had full access to all of the data in the study and had final responsibility
682 for the decision to submit for publication.

683

684 **Additional Clinical and Functional Measures**

685

686 Additional measures of clinical and functional included the Scale for Assessment of Negative
687 Symptoms (SANS), Hamilton Depression Scale (HAM-D) and Hamilton Anxiety Scale
688 (HAM-A), and the World Health Organisation Quality of Life Scale -Brief (WHOQoL-
689 BREF). Substance use was measured using the World Health Organisation Alcohol, Smoking
690 and Substance Involvement Screening Test (WHO-ASSIST). Duration of untreated psychosis
691 was measured using clinical interview.

692

693 **Antipsychotic and Concomitant Medication**

694

695 Concomitant medications were permitted during the trial, except for additional antipsychotics
696 or mood stabilisers (rates of concomitant medications use are provided in Supplementary
697 Table 2). Four patients within the PIPT group were switched to open-label antipsychotic
698 medication before the 3-month MRI scan and were excluded from the primary analysis. After
699 termination of the randomization phase at 6 months, five patients in the PIPT group were
700 exposed to antipsychotic medication between the 3-month and 12-month scan. We examined
701 the impact of this exposure in our analysis of the 12-month data, as detailed below. Mean
702 cumulative dose and rates of exposure for both patient groups at each timepoint are provided

703 in [Supplementary Table 1](#). Duration of untreated psychosis (DUP) was assessed using a
704 clinical interview.

705

706

707 **MRI Acquisition and Pre-processing**

708

709 A 3-T Siemens Trio Tim scanner located at the Royal Children's Hospital in Melbourne,
710 Australia, was used to acquire a high resolution structural T1-weighted Magnetisation-
711 Prepared Rapid Gradient Echo (MPRAGE) scan for each participant. Image acquisition
712 parameters at each timepoint were as follow: 176 sagittal slices, with a 1mm³ voxel size,
713 bandwidth 236 Hz/pixel, FOV=256×256 mm, matrix 256×256, 2300 ms repetition time, and
714 2.98 echo time and a 9 -degree flip angle.

715

716 Prior to pre-processing, all raw T1w images were visually examined for artefacts and then
717 subjected to an automated quality control procedure⁴⁹. Four patient MRI scans did not pass
718 image quality control and were excluded due to excessive head movement (n=1) or image
719 artefacts (n=3). The remaining scans were pre-processed using the longitudinal pipeline of
720 the Computational Anatomy Toolbox²⁵ (version r1113) for the Statistical Parametric
721 Mapping 12 (SPM12) software⁵⁰ running in Matlab version 2015a. Briefly, for each
722 participant, the T1w images from all available timepoints were rigidly realigned to correct for
723 differences in head position within-subject, and a subject-specific mean image was calculated
724 and used as a reference in a subsequent realignment of all T1w images across all timepoints.
725 The mean image was segmented into grey matter, white matter, and cerebrospinal fluid, and
726 normalised using the Diffeomorphic Anatomical Registration using Exponentiated Lie
727 algebra algorithm (DARTEL)⁵⁰. The resulting spatial normalisation parameters were then
728 applied to the segmentation of the bias-corrected individual images for all available
729 timepoints, and the resulting native space segmentation was used to calculate overall total
730 intracranial volume and total GMV volume (ml) using FSLstats. The grey matter images
731 were then again realigned to a DARTEL normalised template. Finally, the voxel level
732 intensities were modulated by both the linear and non-linear Jacobian determinants derived
733 from the previous spatial normalisation to preserve the total amount of grey matter. Finally,
734 the resulting modulated and normalised grey matter images were spatially smoothed using an
735 8mm Gaussian kernel.

736

737

738 **Statistical Analysis - Additional Details**

739

740 Our secondary analysis included the 12-month follow-up timepoint, with the contrast of
741 interest was a linear polynomial contrast examining differences in linear trend between the
742 three groups. We constrain our contrasts in this way, because our hypotheses concern linear
743 interactions between group and time over the follow-up period (as per [Figure 1](#)). The
744 treatment period for the trial ended after 6-months. Thus, in principle, clinicians and patients
745 were no longer bound by the treatment protocol after this point. In practice, four PIPT
746 patients commenced antipsychotic medication in this intervening period, in addition to the
747 four patients who had commenced at the 3-month timepoint. Thus, between the 3-month and
748 12-month scan, a total of eight PIPT patients commenced antipsychotics, whereas all MIPT
749 patients continued medication with varying degrees of exposure. We thus specified a
750 covariate quantifying cumulative exposure to antipsychotics (olanzapine equivalent,
751 milligrams) for all eight patients within the PIPT group who were exposed to medication at
752 the 3-month or 12-month timepoint. This procedure allowed us to statistically adjust for
753 antipsychotic exposure in the PIPT group when attempting to disentangle the long-term
754 effects of illness and medication exposure on GMV. To ensure that this approach did not
755 substantially influence the results, we repeated the analysis after removing the eight
756 antipsychotic-exposed patients from the PIPT group. The results were largely consistent (see
757 [Supplementary Figure 1](#)).

758

759 We investigated the potentially confounding effects of DUP, concomitant medication, and
760 substance use on GMV change in each region showing a significant group x time interaction.
761 The effect of DUP prior to recruitment was examined using (1) a one-way ANOVA to
762 examine baseline differences between three DUP strata (0-30 days, 31-90 days, and >90
763 days); and (2) a two-way ANOVA to assess whether there was a significant interaction effect
764 between time, DUP stratum, and treatment group. To study the effects of non-antipsychotic
765 medications (see [Supplementary Table 2](#)), we conducted a three separate two-way ANOVA
766 testing for an interaction between time and percentage patients who received each of the three
767 classes of concomitant medication (benzodiazepines, antidepressants and other psychotropic
768 medication) during the treatment period (the “other” category included people taking
769 zopiclone, dexamethasone, benztropine and clonidine). To assess the effect of substance use,

770 we ran Spearman correlations between regional GMV change and either the WHO-ASSIST
771 total substance use score or the cannabis use sub-score.

772

773 We assessed the functional impact of any regions showing a statistically significant group by
774 time interaction by correlating percent change in GMV over time (measured by the first
775 eigenvariate of the region, adjusted for covariates) with percent change in scores on the pre-
776 registered⁵¹ primary outcomes of the clinical trial; namely the SOFAS and BPRS-4 total
777 scores. Associations were quantified using Spearman's rank correlations with the threshold
778 for significance set at $p < .025$ (Bonferroni-adjusted for two comparisons). Additional
779 exploratory correlations between all available clinical and functional scales were Bonferroni-
780 corrected for ten comparisons ($p < .005$).

781

782

783 Results of the Baseline Analysis at an Uncorrected Threshold

784 At an uncorrected threshold ($k > 10$, $p < 0.001$; [Supplementary Table 3](#)), patients showed
785 reduced GMV within the right postcentral gyrus, right supramarginal gyrus, right frontal
786 pole, right insula, middle temporal gyrus, and left hippocampus. As expected, no significant
787 total ($F = 0.530$, $p = 0.470$) or voxel-level GMV differences were found between the MIPT
788 and PIPT groups at baseline at either corrected or uncorrected thresholds.

789

790 Results of the Confounding Variables Analyses

791

792 The effect of DUP on baseline pallidal volume was not significant ($F = .011$, $p = .918$), nor
793 was the interaction between DUP and treatment group on percentage change in pallidal
794 volume between baseline and 3 months ($F = .240$; $p = .628$). Similarly, the interactions
795 between treatment group and use of benzodiazepines ($F = 1.01$; $p = .359$), antidepressants (F
796 $= .552$; $p = .463$) or other psychotropic medication ($F = 2.05$; $p = .163$) on percentage change
797 in pallidal volume between baseline and three months were not significant. We also found no
798 significant correlation between percentage change in pallidal volume and total substance use
799 ($\rho = .049$; $p = .786$) or cannabis use ($\rho = -.186$; $p = .300$).

800

801

802

803 Supplementary Table 1 – Cumulative antipsychotic exposure (in Olanzapine milligram equivalents)

	Baseline	3-months	12-months
PIPT, mg (M, SD)	0.16 (0.59)	78.5 (216) ¹	608 (1111)
MIPT, mg (M, SD)	1.03 (5.57)	420 (248)	1311 (1011)

804 ¹ Note: In our primary analysis, the 4 patients within the placebo (PIPT) group who were exposed to
805 antipsychotic medication at amounts greater than the study inclusion criteria at the 3-month timepoint were
806 excluded from the analysis, thus cumulative antipsychotic exposure of the analysis sample was 4.57mg (14.5)
807

808

809 Supplementary Table 2 – Percentage of each treatment group who received each class of concomitant
810 medication between baseline and 3-months

	Benzodiazepine	Antidepressant	Other ¹
PIPT, %	30.0	56.7	30.0
MIPT, %	62.0	51.7	41.4

811 ¹ This category included people taking zopiclone, dexamethasone, benztropine and clonidine.
812

813

814


815

816 Supplementary Table 3 – Regions showing reduced grey matter volume in patients at baseline at an uncorrected
threshold ($p < .001$)

<i>Baseline Comparison</i>	Hemisphere	Peak MNI _{spm} coordinates (x,y,z)	Cluster size voxels (mm ³)
Supramarginal gyrus	Right	52.5, -36, 37.5	191 (645)
Hippocampus	Left	-31.5, -28.5, -12	94 (317)
Middle-Temporal cortex	Right	49.5, -58.5, 3	93 (314)
Frontal pole	Right	13.5, 60, 7.5	57 (192)
Postcentral gyrus	Right	18, -36, 48	30 (101)
Insula Cortex	Right	31.5, 15, -1.5	21 (71)

817

818



819

820

Supplementary Figure 1 – Red clusters indicate anatomical locations where differences in linear trend ($p < 0.001$, uncorrected) were detected between baseline and 12 months. In this analysis, patients in the placebo group who were exposed to antipsychotic medication during the 12 months were removed from the analysis.

822

Bottom row of each panel shows the nature of the interaction. Abbreviations: PIPT = placebo plus intensive psychosocial therapy, MIPT = antipsychotic medication plus intensive psychosocial therapy.


823

824

825

826

827



828

829

Supplementary Figure 2 – Red clusters indicate anatomical locations where significant group by time

830

interactions ($p < 0.001$, uncorrected) were detected between baseline and 3 months. Bottom row shows the

831

nature of the interaction. A) left lateral occipital cortex; B) left cerebellum; C) left inferior temporal


832

left precuneus; E) right orbitofrontal. Abbreviations: PIPT = placebo plus intensive psychosocial therapy, MIPT

833

= antipsychotic medication plus intensive psychosocial therapy.

834



835

836

837

Supplementary Figure 3 – Red clusters indicate anatomical locations where differences in linear trend ($p < 0.001$, uncorrected) were detected between baseline and 12 months. Bottom row of each panel shows the nature of the interaction. A) right dorsolateral superior frontal gyrus; B) left dorsolateral superior frontal gyrus; C) right superior orbito-frontal gyrus; D) right middle orbito-frontal gyrus; E) left superior medial frontal gyrus; F) right cerebellar crus I; G) right middle temporal gyrus; H) right temporal pole; I) right cerebellar VIII;

841


Abbreviations: PIPT = placebo plus intensive psychosocial therapy, MIPT = antipsychotic medication plus intensive psychosocial therapy.

844

845

846

847



848

849

850 Supplementary Figure 4 – Volume of pallidal cluster at 12-months follow-up. A) The principal pallidal GMV
 851 eigenvariate for each group at baseline and 3-month follow-up, and 12-month follow-up, adjusted for model
 852 covariates. The pattern of results remained largely the same after patients in the patients in the PIPT group who
 853 were exposed to antipsychotic medication were removed from the analysis.

854

855

856

857

858 Results from White Matter Analyse at an Uncorrected Threshold

859 At an uncorrected threshold ($k > 10$, $p < 0.001$), interaction effects were detected within the
 860 white matter of the right cerebellar lobule V and crus II. These effects were consistent with a
 861 putative neurotoxic effect and an unmodified illness-related change, respectively
 862 ([Supplementary Figure 3b-c](#)).


863

864 No significant interactions were detected when including the 12-month time point. At an
 865 uncorrected threshold ($k > 10$, $p < 0.001$), an interaction effect consistent with a unmodified
 866 illness-related change was detected within left frontal white matter ([Supplementary Figure 4](#)).

867


868

869



870
871
872
873
874
875
876
877
878
879

Supplementary Figure 5 – The principal cerebellar white matter eigenvariate for each group at baseline and 3-month follow-up, adjusted for model covariates. Error bars show 95% confidence intervals.
A) Cerebellar lobule IX cluster ($p < 0.05$, FWE-corrected) B) cerebellar lobule V ($p < 0.001$, uncorrected), C) Cerebellar crus II ($p < 0.001$, uncorrected)



880
881
882

Supplementary Figure 6 – Red clusters indicates frontal white matter where differences in linear trend ($p < 0.001$, uncorrected) were detected between baseline and 12 months.